Publications

Publications search (many options)

Publika data base

Publications (original articles or review articles) published in 2013 from OUS - Metastasis - biology and therapy

13 publications found

Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E, Mælandsmo GM, Prasmickaite L (2013)
Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties
Cancer Lett, 344 (1), 28-39
PubMed 24215866

Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O (2013)
Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts
Anticancer Res, 33 (9), 3615-21
PubMed 24023287

Esmaeili M, Bathen TF, Engebråten O, Mælandsmo GM, Gribbestad IS, Moestue SA (2013)
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts
Magn Reson Med, 71 (6), 1973-81
PubMed 23878023

Friedman R, Boye K, Flatmark K (2013)
Molecular modelling and simulations in cancer research
Biochim Biophys Acta, 1836 (1), 1-14
PubMed 23416097

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
PubMed 23326369

Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu F (2013)
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer
Proc Natl Acad Sci U S A, 110 (28), E2572-81
PubMed 23798432

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
PubMed 24900104

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E (2013)
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts
Acta Oncol, 52 (7), 1566-72
PubMed 23984812

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O (2013)
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
PubMed 24192926

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G (2013)
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Breast Cancer Res, 15 (1), R16
PubMed 23448424

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS (2013)
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
PubMed 23908122

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
PubMed 23942067

Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM (2013)
Osteopontin is a prognostic biomarker in non-small cell lung cancer
BMC Cancer, 13, 540
PubMed 24215488